Posted by Michael Wonder on 09 Jul 2023
After five years of successful experience internationally, Biocon Biologics’ Hulio biosimilar to Humira, now available in the United States
3 July 2023 - Biocon Biologics today announced that Hulio (adalimumab-fkjp) injection, a biosimilar to Humira (adalimumab), is now available to patients in the United States after five years of experience in Europe and two years in Canada.
Biocon Biologics, which recently announced its acquisition of Viatris’ global biosimilars business, has secured multiple biosimilar approvals in the US., Europe, and over 100 countries across the globe.
